Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma

Future Oncology

Volumn 10, Issue 9, 2014, Pages 1559-1570

  King, Judy W ^a   Nathan, Paul D ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

MEK inhibitor; melanoma; trametinib

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAF GENE; CANCER PATIENT; ENZYME INHIBITION; HUMAN; METASTATIC MELANOMA; MUTANT; ONCOGENE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOMATIC MUTATION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; MELANOMA; MISSENSE MUTATION; MORTALITY; PATHOLOGY; SECONDARY; SKIN NEOPLASMS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; MAP KINASE KINASE KINASES; MELANOMA; MUTATION, MISSENSE; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; SKIN NEOPLASMS;

EID: 84906549120     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.89     Document Type: Article

References (82)

1. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N. Engl. J. Med. 351(10), 998-1012 (2004
2. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010
3. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507-2516 (2011
4. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J. Clin. Oncol. 26(32), 5275-5283 (2008
5. Schadendorf D, Hodi F, Robert C et al. Pooled analysis of long-term survival data from Phase II and Phase Iii trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. Presented at: European Cancer Congress 2013 (ECCO-ESMO-ESTRO). Amsterdam, The Netherlands, 27 September-1 October 2013 (Abstract 24
6. Ku GY, Yuan J, Page DB et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 116(7), 1767-1775 (2010
7. Bouwhuis MG, Ten Hagen TL, Suciu S, Eggermont AM. Autoimmunity and treatment outcome in melanoma. Curr. Opin. Oncol. 23(2), 170-176 (2011
8. Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23(25), 6043-6053 (2005
9. Downey SG, Klapper JA, Smith FO et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin. Cancer Res. 13(22 Pt 1), 6681-6688 (2007
10. Wolchok JD, Weber JS, Hamid O et al. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun. 10, 9 (2010
11. Weisberg E, Manley PW, Breitenstein W et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7(2), 129-141 (2005
12. Yuan J, Adamow M, Ginsberg BA et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc. Natl Acad. Sci. USA 108(40), 16723-16728 (2011
13. Prieto PA, Yang JC, Sherry RM et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin. Cancer Res. 18(7), 2039-2047 (2012
14. Hamid O, Schmidt H, Nissan A et al. A prospective Phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J. Transl. Med. 9, 204 (2011
15. Ji RR, Chasalow SD, Wang L et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. 61(7), 1019-1031 (2012
16. Jiveskog S, Ragnarsson-Olding B, Platz A, Ringborg U. N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J. Invest. Dermatol. 111(5), 757-761 (1998
17. Houben R, Becker JC, Kappel A et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J. Carcinog. 3(1), 6 (2004
18. Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353(20), 2135-2147 (2005
19. Sosman JA, Kim KB, Schuchter L et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366(8), 707-714 (2012
20. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 417(6892), 949-954 (2002
21. Chapman PB, Hauschild A, Robert C et al. Updated overall survival (OS) results for BRIM-3, a Phase Iii randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF V600E-mutated melanoma. J. Clin. Oncol. 30(Suppl.), 8502a (2012
22. Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, Phase 3 randomised controlled trial. Lancet 380(9839), 358-365 (2012
23. Wilson TR, Fridlyand J, Yan Y et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487(7408), 505-509 (2012
24. Nazarian R, Shi H, Wang Q et al. Melanomas acquire resistance to B-RAFV600E inhibition by RTK or N-RAS upregulation. Nature 468(7326), 973-977 (2010
25. Wagle N, Emery C, Berger MF et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29(22), 3085-3096 (2011
26. Poulikakos PI, Persaud Y, Janakiraman M et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAFV600E. Nature 480(7377), 387-390 (2011
27. Su F, Bradley WD, Wang Q et al. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res. 72(4), 969-978 (2012
28. Shi H, Moriceau G, Kong X et al. Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun. 3, 724 (2012
29. Smalley KS, Lioni M, Dalla PM et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol. Cancer Ther. 7(9), 2876-2883 (2008
30. Paraiso KH, Xiang Y, Rebecca VW et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 71(7), 2750-2760 (2011
31. Johannessen CM, Boehm JS, Kim SY et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468(7326), 968-972 (2010
32. Shi H, Hugo W, Kong X et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 4(1), 80-93 (2014
33. Flaherty KT, Robert C, Hersey P et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367(2), 107-114 (2012
34. Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KS. Paradoxical oncogenesis-the long-term effects of BRAF inhibition in melanoma. Nat. Rev. Clin. Oncol. 10(7), 390-399 (2013
35. Joseph EW, Pratilas CA, Poulikakos PI et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl Acad. Sci. USA 107(33), 14903-14908 (2010
36. Hatzivassiliou G, Song K, Yen I et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464(7287), 431-435 (2010
37. Heidorn SJ, Milagre C, Whittaker S et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140(2), 209-221 (2010
38. Callahan MK, Rampal R, Harding JJ et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N. Engl. J. Med. 367(24), 2316-2321 (2012
39. Zimmer L, Hillen U, Livingstone E et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J. Clin. Oncol. 30(19), 2375-2383 (2012
40. Andrews M, Behren A, Chiohn F et al. Colorectal cancer promoted in a patient receiving dabrafenib (GSK2118436) with combination with MEK1/2 inhibitor trametinib (GSK1120212). Pigment Cell Melanoma Res. 25, 842 (2012
41. Gilmartin AG, Bleam MR, Groy A et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin. Cancer Res. 17(5), 989-1000 (2011
42. Iverson C, Larson G, Lai C et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 69(17), 6839-6847 (2009
43. Lorusso PM, Adjei AA, Varterasian M et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J. Clin. Oncol. 23(23), 5281-5293 (2005
44. Adjei AA, Cohen RB, Franklin W et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 26(13), 2139-2146 (2008
45. Brown AP, Carlson TC, Loi CM, Graziano MJ. Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemother. Pharmacol. 59(5), 671-679 (2007
46. Infante JR, Fecher LA, Falchook GS et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a Phase 1 dose-escalation trial. Lancet Oncol. 13(8), 773-781 (2012
47. Falchook GS, Long GV, Kurzrock R et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a Phase 1 dose-escalation trial. Lancet 379(9829), 1893-1901 (2012
48. Kim KB, Kefford R, Pavlick AC et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J. Clin. Oncol. 31(4), 482-489 (2013
49. Schadendorf D, Flaherty T, Hersey P et al. Overall survival update on METRIC (NCT01245062), a randomized Phase 3 study to assess efficacy of trametinib compared with chemotherapy in patients with BRAF V600E/K mutation-positive advanced or metastatic melanoma. Philadelphia, PA, USA, 17-20 November 2013 (AbstractLBA8509
50. Friday BB, Yu C, Dy GK et al. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res. 68(15), 6145-6153 (2008
51. Yeh TC, Marsh V, Bernat BA et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res. 13(5), 1576-1583 (2007
52. Banerji U, Camidge DR, Verheul HM et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a Phase I open-label multicenter trial in patients with advanced cancer. Clin. Cancer Res. 16(5), 1613-1623 (2010
53. Ascierto PA, Schadendorf D, Berking C et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label Phase 2 study. Lancet Oncol. 14(3), 249-256 (2013
54. Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma. http://clinicaltrials.gov/show/ NCT01763164
55. Rosen L, LoRusso P, Wee W et al. A first-in-human Phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors. Presented at: 102nd Annual Meeting of the American Association for Cancer Research. Orlando, FL, USA, 2-6 April 2011
56. A Phase 3 Study Comparing GDC-0973 (Cobimetinib), a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma. http://clinicaltrials.gov/show/NCT01689519
57. Trunzer K, Pavlick AC, Schuchter L et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J. Clin. Oncol. 31(14), 1767-1774 (2013
58. Emery CM, Vijayendran KG, Zipser MC et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl Acad. Sci. USA 106(48), 20411-20416 (2009
59. Nikolaev SI, Rimoldi D, Iseli C et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat. Genet. 44(2), 133-139 (2012
60. Villanueva J, Vultur A, Lee JT et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18(6), 683-695 (2010
61. Little AS, Balmanno K, Sale MJ et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci. Signal. 4(166), ra17 (2011
62. Celtikci B, Carson R, Van Schaeybroeck S, Johnston P. The role of JAK1/2-STAT3 as acute resistance mechanism to MEK inhibition in BRAF mutant colorectal cancer cell lines. Presented at: National Cancer Research Institute. Liverpool, UK, 3-6 November 2013 (Abstract B166
63. Smith MP, Ferguson J, Arozarena I et al. Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. J. Natl Cancer Inst. 105(1), 33-46 (2013
64. Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int. J. Cancer 125(10), 2332-2341 (2009
65. Wee S, Jagani Z, Xiang KX et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 69(10), 4286-4293 (2009
66. Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367(18), 1694-1703 (2012
67. A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma. http://clinicaltrial.gov/show/NCT01584648
68. Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma (COMBI-v). http://clinicaltrial.gov/ show/NCT01597908
69. A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection. (COMBI-AD). http://clinicaltrials.gov/show/NCT01682083
70. Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IiiB-C BRAF V600 Mutation Positive Melanoma. http://clinicaltrials.gov/show/NCT01972347
71. Das TM, Salangsang F, Landman AS et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494(7436), 251-255 (2013
72. Huang W, Yang AH, Matsumoto D et al. PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. J. Ocul. Pharmacol. Ther. 25(6), 519-530 (2009
73. Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma. http://clinicaltrials.gov/show/NCT01979523
74. Trametinib With GSK2141795 in BRAF Wild-type Melanoma. http://clinicaltrials.gov/show/NCT01941927
75. Coit DG, Andtbacka R, Anker CJ et al. Melanoma. J. Natl Compr. Canc. Netw. 10(3), 366-400 (2012
76. Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, Riely GJ. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin. Cancer Res. 17(19), 6298-6303 (2011
77. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369(2), 122-133 (2013
78. Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067). http://clinicaltrials.gov/show/NCT01844505
79. Ribas A, Robert C, Daud A et al. Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma. J. Clin. Oncol. 31(Suppl.), Abstract 9009 (2013
80. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012
81. Ribas A, Hodi S, Callahan M et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368, 1365-1366 (2013
82. Study of Dabrafenib +/-Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma. http://clinicaltrial.gov/show/NCT01767454